Confusion and missing financial information from Town Hall plague Wilton's Board of Finance meeting. Questions remain unanswered, causing member frustration.
Earnings call Kuros Biosciences posted FY25 revenue of $146.1M (+72% YoY), adjusted EBITDA of $19.6M (13.4% margin), and first-ever net profit of $2.6M, exceeding guidance. Management guides for at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results